Zymeworks Inc. announced that their bispecific antibody, zanidatamab, has received conditional approval from China's National Medical Products Administration (NMPA) for treating previously treated, ...
Hosted on MSN
Oral drug demonstrates promising anti-tumor activity in patients with advanced lung cancer
"FDA approval of sevabertinib would introduce another targeted therapy option, one that precisely targets this mutation. This drug has demonstrated meaningful clinical activity with a manageable ...
Telisotuzumab vedotin-tllv is now approved for advanced non-squamous NSCLC with high c-Met overexpression after prior treatment. The drug targets c-MET expression, impacting approximately 25% of EGFR ...
Datroway received FDA accelerated approval for EGFR-mutated NSCLC after progression on EGFR-targeted therapy and platinum-based chemotherapy. Clinical trials showed a 45% overall response rate and a ...
The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell lung cancer (NSCLC) associated with EGFR exon 20 insertions, the agency said.
The FDA approved elinzanetant (Lynkuet), a new type of nonhormonal drug to treat disruptive menopausal hot flashes, Bayer announced on Friday. Elinzanetant is now the first and only dual neurokinin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback